flutamide / Generic mfg. - LARVOL DELTA

ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - P4 | N=10 | Terminated | Sponsor: University of Colorado, Denver | Completed ➔ Terminated; Study completed

Trial termination • Cardiovascular • Genito-urinary Cancer • Hypertension • Nephrology • Oncology • Prostate Cancer • Renal Disease • Solid Tumor

Short-term Androgen Deprivation Therapy and High-dose Radiotherapy in Intermediate- and High-risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase 3 Trial. (PubMed, Eur Urol) - "STADT is a well-tolerated and effective strategy that can enhance oncological outcomes when combined with high-dose RT, particularly for patients with intermediate- or high-risk prostate cancer."

Journal • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial (ASTRO 2024) - "RT dose was 80 Gy in both arms and STADT was monthly triptorelin and daily flutamide for a total duration of 4 months, starting 2 months before irradiation. STADT improves disease-free survival in intermediate and high-risk prostate cancer patients receiving high dose (80 Gy) RT, without any deterioration in the safety profile."

Clinical • Late-breaking abstract • P3 data • Gastrointestinal Disorder • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Effects of Mebendazole and Flutamide Combination in Prostate Cancer Cell Lines: a Comprehensive in Vitro Analysis. (PubMed, Cell Physiol Biochem) - "Mebendazole in combination with flutamide reduced dose of flutamide and increased the sensitivity of prostate cancer cells to treatment. Therefore, this combination may represent a promising in vitro strategy that warrants further mechanistic and in vivo investigation."

IO biomarker • Journal • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BAX • BCL2 • CDH1 • CDH2 • HIF1A • KLK3 • TUBB1 • TUBB3 • VEGFC

NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov) - P2/3 | N=612 | Active, not recruiting | Sponsor: NRG Oncology | Completed ➔ Active, not recruiting | Trial completion date: Oct 2025 ➔ Oct 2030

Enrollment closed • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Novel inhibitors of BCRP found among drugs used in the treatment of cancer. (PubMed, Eur J Pharm Sci) - "Moreover, the model suggested that midostaurin, cabozantinib, and alpelisib could almost fully inhibit intestinal BCRP, nearly doubling rosuvastatin exposure (1.83- to 1.94-fold). Entrectinib, alpelisib, flutamide, abiraterone, and capecitabine were predicted to increase rosuvastatin exposure by 1.45- to 1.63-fold through BCRP inhibition. FAERS analysis indicated a higher frequency of rhabdomyolysis reports when abiraterone was co-administered with rosuvastatin compared with all reports without abiraterone, with a reporting odds ratio of 17.3. This study identified multiple previously unrecognized BCRP inhibitors, highlighting the potential for clinically relevant BCRP‑mediated drug-drug interactions in oncology patients."

Journal • Breast Cancer • Oncology • Solid Tumor

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "The addition of enzalutamide to standard of care showed sustained improvement in overall survival for patients with metastatic hormone-sensitive prostate cancer and should be considered as a treatment option for eligible patients."

Journal • Metastases • P3 data • Alzheimer's Disease • Cardiovascular • CNS Disorders • Fatigue • Febrile Neutropenia • Genito-urinary Cancer • Hematological Disorders • Hypertension • Neutropenia • Oncology • Prostate Cancer • Solid Tumor

Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. (PubMed, Oncologist) - P2 | "The combination of flutamide+PROSTVAC did not improve outcomes in men with nmCRPC compared with flutamide alone. (ClinicalTrials.gov Identifier: NCT00450463)."

Clinical • Journal • Metastases • Genito-urinary Cancer • Immune Modulation • Oncology • Prostate Cancer • Solid Tumor

Treatment patterns and survival outcomes in metastatic castration-resistant prostate cancer in the Brazilian population: LACOG 1818. (ASCO-GU 2025) - P | "LACOG 1818 study demonstrated significant disparities in treatment patterns and survival outcomes between public and private settings for Brazilian pts with mCRPC. Pts with private coverage had longer OS and CSS. These findings underscore the need for improved access to novel therapies and comprehensive cancer care in Brazil's public healthcare system to reduce survival disparities."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - P3 | N=2753 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Dec 2033 ➔ Dec 2038

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CD4

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - P3 | N=2050 | Active, not recruiting | Sponsor: NRG Oncology | Trial completion date: Nov 2026 ➔ Nov 2031

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Sex-Based Differences in Severe Trauma and Hemorrhagic Shock: A Systematic Review of Pre-Clinical and Veterinary Animal Studies. (PubMed, Shock) - "Preclinical evidence confirms sex-dependent resilience in T/HS, primarily driven by sex steroids and immune-vascular modulation. To bridge the translational gap, clinical studies should adopt sex-stratified analyses and prospectively record hormonal status. Future preclinical research must prioritize standardized reporting and the use of large-animal or uncontrolled hemorrhage models to validate these findings for critical care."

Journal • Preclinical • CNS Disorders • Critical care • Hematological Disorders • Infectious Disease • Inflammation • Septic Shock • Vascular Neurology

Absolute 19F-qNMR Quantification of Fluorinated Pharmaceuticals: Fluorometholone, Flurbiprofen, and Flutamide. (PubMed, Chem Pharm Bull (Tokyo)) - "The average purity values determined by 19F-qNMR were 98.79 ± 0.62% (n = 7) or 98.62 ± 0.34% (n = 6) for FM, 99.84 ± 0.40% (n = 9) for FP, and 99.84 ± 0.48% (n = 9) for FT; these values were in good agreement with those determined by 1H-qNMR (99.23 ± 0.41% (n = 9), 100.04 ± 0.34% (n = 10), and 99.67 ± 0.38% (n = 10), respectively). Collectively, these results indicate that 19F-qNMR is a reliable and reproducible technique for absolute quantification of fluorinated pharmaceuticals, supporting its application in pharmaceutical quality control and regulatory assessment."

Journal

Brain Sex Steroid-Mediated Intergenerational Sex-Specific Neurocognitive Effects of Paternal Sevoflurane Exposure in Rats. (PubMed, Anesth Analg) - "These findings suggest that male-specific neurodevelopmental abnormalities following paternal preconception sevoflurane exposure arise from stress- and inflammation-programmed increases in brain-derived testosterone during the critical brain masculinization period, involving both AR and E2 signaling."

Journal • Preclinical • CNS Disorders • Developmental Disorders • Inflammation • Mood Disorders • Psychiatry • AR • ER

Real-world trends in anti-androgen prescribing and associated costs for prostate cancer in Japan: a nationwide analysis. (PubMed, Jpn J Clin Oncol) - "In Japan, ARSI use and related expenditures increased substantially between 2016 and 2023. Despite modest prescription volumes, ARSIs accounted for most anti-androgen-related costs."

Journal • Real-world evidence • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Characterization of Ozonation Transformation Products of Flutamide and Azathioprine by UHPLC-Ion Mobility-High-Resolution Mass Spectrometry. (PubMed, ACS ES T Water) - "These results highlight the importance of considering transformation products during ozonation and suggest possible nitration reactions when ozone is generated from ambient air. Further experiments are needed to confirm this."

Journal • Oncology

Recent developments in electrochemical sensors for anticancer drugs analysis: Nanostructured innovations. (PubMed, Nanomedicine) - "Characteristics like broad linear ranges, remarkable stability, and ultralow detection limit enable the accurate measurement of drugs including dasatinib (DAS), flutamide (FLUT), thiopurines, and doxorubicin (DOX). High recovery and minimal sample preparation are demonstrated by real sample analysis in serum and urine. Overall, this study emphasizes the revolutionary potential of nanomaterial-enhanced electrochemical sensors as beneficial, versatile platforms for TDM."

Journal • Review • Oncology

Androgen receptor activation is involved in maintaining goal-directed behavior in levonorgestrel-treated female rats. (PubMed, Horm Behav) - "However, LNG-implanted rats treated with flutamide during training displayed habitual behavior, suggesting that the androgenic effects of LNG are responsible, at least in part, for delaying habit expression in intact female rats. This finding suggests that the androgenic properties of LNG are exerting significant effects on cognitive processes related to behavioral flexibility in the female brain."

Journal • Preclinical • Endocrine Disorders • AR

S-scheme Bi2S3/FeIn2S4 heterojunction for ultrasensitive photoelectrochemical detection of flutamide. (PubMed, Talanta) - "The designed sensor exhibits good repeatability and long-term storage stability (>92.8%). Moreover, this sensor was successfully applied in human serum and urine, with recovery rates ranging from 96.9% to 100.2%."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Metformin and Flutamide Combination Therapy's Efficacy and Safety in Prostate Cancer Cell Lines. (PubMed, Prostate Cancer) - "Additionally, it mitigated the hepatotoxic effects of flutamide. Therefore, this combination may represent a new treatment strategy for PCa."

IO biomarker • Journal • Preclinical • Genito-urinary Cancer • Hepatology • Liver Failure • Oncology • Prostate Cancer • Solid Tumor • BAX • BCL2 • CDH1 • HIF1A • KLK3 • VEGFC

Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer. (PubMed, Gut Microbes) - "Clinical sample analysis revealed substantial interpatient variability, and patients could be categorized into subgroups with high or low metabolic capability. These findings provide new insights into personalized prostate cancer therapy, highlight the role of the gut microbiota in Flutamide response and suggest a strategy for optimizing antiandrogen treatments."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Efficient extraction of fluorinated non-steroidal androgen receptor antagonists on a novel trifluoromethyl functionalized magnetic microporous organic network. (PubMed, J Chromatogr A) - "Based on the hydrophobicity and fluorine-containing characteristics of NSAAs, this study designed and prepared a novel trifluoromethyl functionalized magnetic microporous organic network (MMON-CF3) for the efficient and selective magnetic solid-phase extraction (MSPE) of three typical NSAAs, namely flutamide, bicalutamide, and enzalutamide, from environmental water samples before HPLC-UV quantification. Under optimum extraction parameters, the developed MMON-CF3-MSPE-HPLC-UV method demonstrated satisfactory analytical performance for the three analytes, including low limits of detection (0.1-0.2 μg L-1), a broad linear range (0.5-1000 μg L-1), high enrichment factors (91.2-95.6), minimal adsorbent dosage (3 mg), and fast extraction equilibrium (6 min). The present work underscores the promising application potential of fluorinated MON-based materials in the sample pretreatment of fluorinated pharmaceutical contaminants from complicated environmental matrices."

Journal

Combination Therapy in Androgenetic Alopecia: A Network Meta-Analysis of Minoxidil and Other Pharmacological Agents. (PubMed, Aesthetic Plast Surg) - "Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic alopecia. However, due to the limitations of the existing research, more high-quality, multi-center studies are needed to support our viewpoint."

Journal • Retrospective data • Review • Alopecia • Immunology

Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system. (PubMed, Int Urol Nephrol) - "This study identified seven antiandrogens with pharmacovigilance signals, among which the signal for darolutamide was detected for the first time. The dual-level analysis generated the hypothesis that bicalutamide-associated ILD may have a greater tendency to evolve into a fibrotic phenotype. The observed Japanese predominance in reporting likely reflects regulatory and reporting-related factors rather than a true biologic excess risk. Female-related ILD reports represent solely a signal-generating observation. These findings are exploratory and require further validation."

Adverse events • Journal • Breast Cancer • Fibrosis • Immunology • Interstitial Lung Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Late gestational exposure to flutamide alters stromal composition and immune landscape in the rat mammary gland during pre-puberty, peri-puberty, and adulthood. (PubMed, Toxicol Sci) - "Cytokine profiling revealed a reduced adaptive immune response at PND46 and PND90, and second harmonic generation imaging demonstrated changes in collagen fiber orientation and density across all developmental stages. These data indicate that prenatal androgen signaling is essential for proper stromal development and the establishment of early transcriptional networks in the mammary gland, with only minor long-term effects on glandular architecture in adult nulliparous females."

Journal • Preclinical